Johnson & Johnson’s $3.05 Billion Acquisition of Halda Therapeutics OpCo, Inc.

On November 17, 2025, Johnson & Johnson announced it has entered into a definitive agreement to acquire Halda Therapeutics OpCo, Inc., a clinical‑stage biotechnology company with a proprietary Regulated Induced Proximity TArgeting Chimera (RIPTACTM) platform to develop oral, targeted therapies for multiple types of solid tumors, including prostate cancer, for $3.05 billion in cash. Cravath is representing Johnson & Johnson in connection with the transaction.

The Cravath team is led by partners Robert I. Townsend III and Jin‑Kyu Baek and includes associates Josh Santilli, Evan S. Gabor and Y. Amy Chun on M&A matters; partners J. Leonard Teti II and Andrew T. Davis and associates Carlos Nicholas Obando and Ruth Goldstein Schapiro on tax matters; partner Matthew J. Bobby, of counsel Sarah W. Colangelo and associate Caroline Wyatt on executive compensation and benefits matters; partner Sasha Rosenthal‑Larrea, of counsel Kathryn‑Ann Stamm and associates M. Noa Ma and Liza C. Clark on intellectual property matters; partner Matthew Morreale on environmental matters; and senior attorney Joyce Law and practice area attorney Brian M. Budnick on real estate matters. Leon K. Yang and Alexandra E. Stolfe also worked on M&A matters and Nilofar Vakili also worked intellectual property matters.